Clinical

Dataset Information

0

A randomised double blind placebo controlled trial of infusional subcutaneous octreotide in the management of malignant bowel obstruction at the end of life.


ABSTRACT: Interventions: A phase III randomised, double blind, placebo controlled trial of octreotide (600mcg) delivered by continuous subcutaneous infusion used in conjunction with bolus daily parenteral (subcutaneous or intravenous) dexamethasone (8mg), ranitidine (200mg per 24 hours, either as bolus or continuous subcutaneous infusion) and parenteral hydration (continous subcutaneous or intravenous infusion) of(10mls/kg/24hours) over a maximum of 72 hours. Primary outcome(s): The primary outcome is number of days without an episode of vomiting in the first 72 hours of the study.[72 hours from the start of treatment] Study Design: Purpose: Treatment; Allocation: Randomised controlled trial; Masking: Blinded (masking used);Assignment: Parallel;Type of endpoint: Efficacy

DISEASE(S): Bowel Obstruction In The Setting Of Advanced Cancer,Cancer-other Cancer Types

PROVIDER: 2453927 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

2010-04-29 | GSE21534 | GEO
2010-05-27 | E-GEOD-21534 | biostudies-arrayexpress
2010-05-21 | GSE21909 | GEO
2012-04-11 | E-GEOD-37166 | biostudies-arrayexpress
| 36609 | ecrin-mdr-crc
| 2464067 | ecrin-mdr-crc
2013-06-27 | GSE48311 | GEO
2011-10-18 | E-GEOD-33037 | biostudies-arrayexpress
2010-06-08 | E-GEOD-21909 | biostudies-arrayexpress
2010-06-11 | GSE22278 | GEO